$1.22
Insights on Opko Health, Inc.
Revenue is up for the last 2 quarters, 178.6M → 181.9M (in $), with an average increase of 1.8% per quarter
Netprofit is up for the last 2 quarters, -84.5M → -66.50M (in $), with an average increase of 27.1% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 23.2% return, outperforming this stock by 35.4%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 0.2% return, outperforming this stock by 72.0%
2.43%
Downside
Day's Volatility :3.22%
Upside
0.81%
30.2%
Downside
52 Weeks Volatility :61.98%
Upside
45.54%
Period | Opko Health, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 23.91% | 0.5% | 0.0% |
6 Months | -3.17% | 11.7% | 0.0% |
1 Year | -12.23% | 6.2% | 2.2% |
3 Years | -71.76% | 13.5% | -23.0% |
Market Capitalization | 857.3M |
Book Value | $1.8 |
Earnings Per Share (EPS) | -0.25 |
PEG Ratio | -2.87 |
Wall Street Target Price | 4.25 |
Profit Margin | -21.87% |
Operating Margin TTM | -37.97% |
Return On Assets TTM | -4.73% |
Return On Equity TTM | -12.8% |
Revenue TTM | 863.5M |
Revenue Per Share TTM | 1.15 |
Quarterly Revenue Growth YOY | -1.9% |
Gross Profit TTM | 214.3M |
EBITDA | -52.8M |
Diluted Eps TTM | -0.25 |
Quarterly Earnings Growth YOY | 0.19 |
EPS Estimate Current Year | -0.37 |
EPS Estimate Next Year | -0.26 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 248.36%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 990.3M | ↑ 2.51% |
Net Income | -153.0M | ↓ 49.88% |
Net Profit Margin | -15.45% | ↑ 16.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 901.9M | ↓ 8.93% |
Net Income | -312.0M | ↑ 103.92% |
Net Profit Margin | -34.59% | ↓ 19.14% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | ↑ 59.15% |
Net Income | 30.6M | ↓ 109.8% |
Net Profit Margin | 2.13% | ↑ 36.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 23.64% |
Net Income | -29.5M | ↓ 196.45% |
Net Profit Margin | -1.66% | ↓ 3.79% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↓ 43.42% |
Net Income | -328.0M | ↑ 1011.86% |
Net Profit Margin | -32.66% | ↓ 31.0% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 863.5M | ↓ 14.01% |
Net Income | -188.9M | ↓ 42.42% |
Net Profit Margin | -21.87% | ↑ 10.79% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 179.7M | ↓ 42.0% |
Net Income | -86.0M | ↓ 15.12% |
Net Profit Margin | -47.87% | ↓ 15.15% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 185.4M | ↑ 3.15% |
Net Income | -85.2M | ↓ 0.99% |
Net Profit Margin | -45.95% | ↑ 1.92% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 237.6M | ↑ 28.16% |
Net Income | -18.2M | ↓ 78.64% |
Net Profit Margin | -7.66% | ↑ 38.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 265.4M | ↑ 11.71% |
Net Income | -19.6M | ↑ 7.91% |
Net Profit Margin | -7.4% | ↑ 0.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 178.6M | ↓ 32.71% |
Net Income | -84.5M | ↑ 330.24% |
Net Profit Margin | -47.31% | ↓ 39.91% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 181.9M | ↑ 1.85% |
Net Income | -66.5M | ↓ 21.29% |
Net Profit Margin | -36.56% | ↑ 10.75% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↓ 5.36% |
Total Liabilities | 659.8M | ↓ 11.59% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↓ 5.79% |
Total Liabilities | 694.5M | ↑ 5.26% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 7.09% |
Total Liabilities | 801.5M | ↑ 15.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 2.97% |
Total Liabilities | 714.6M | ↓ 10.84% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↓ 9.68% |
Total Liabilities | 605.7M | ↓ 15.24% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 7.18% |
Total Liabilities | 622.5M | ↑ 2.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 6.11% |
Total Liabilities | 595.7M | ↓ 8.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 2.58% |
Total Liabilities | 605.7M | ↑ 1.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 0.11% |
Total Liabilities | 617.8M | ↑ 2.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 0.49% |
Total Liabilities | 623.6M | ↑ 0.93% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 4.73% |
Total Liabilities | 612.1M | ↓ 1.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 2.19% |
Total Liabilities | 622.5M | ↑ 1.7% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -109.1M | ↑ 18.53% |
Investing Cash Flow | -26.1M | ↓ 44.03% |
Financing Cash Flow | 140.9M | ↑ 130.84% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -172.5M | ↑ 58.07% |
Investing Cash Flow | -13.3M | ↓ 49.19% |
Financing Cash Flow | 175.2M | ↑ 24.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 39.5M | ↓ 122.88% |
Investing Cash Flow | -18.3M | ↑ 38.11% |
Financing Cash Flow | -35.1M | ↓ 120.02% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.3M | ↓ 2.89% |
Investing Cash Flow | 35.9M | ↓ 296.15% |
Financing Cash Flow | -10.4M | ↓ 70.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -32.2M | ↑ 180.87% |
Investing Cash Flow | -4.7M | ↓ 104.32% |
Financing Cash Flow | 8.4M | ↓ 31.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -31.6M | ↓ 1.91% |
Investing Cash Flow | -5.5M | ↑ 17.28% |
Financing Cash Flow | 10.1M | ↑ 20.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.6M | ↓ 28.38% |
Investing Cash Flow | -7.7M | ↑ 40.54% |
Financing Cash Flow | -13.1M | ↓ 229.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -365.0K | ↓ 98.39% |
Investing Cash Flow | -5.5M | ↓ 28.85% |
Financing Cash Flow | 3.5M | ↓ 126.39% |
Sell
Neutral
Buy
Opko Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Opko Health, Inc. | 20.79% | -3.17% | -12.23% | -71.76% | -50.41% |
Idexx Laboratories, Inc. | -7.79% | 23.1% | 1.62% | -12.39% | 110.45% |
Agilent Technologies Inc. | -5.57% | 30.74% | 2.44% | -0.71% | 76.14% |
Thermo Fisher Scientific, Inc. | 0.51% | 29.89% | 7.24% | 15.73% | 109.26% |
Danaher Corp. | -1.07% | 26.91% | 5.73% | -4.77% | 87.73% |
Iqvia Holdings Inc. | -5.55% | 26.87% | 23.16% | 0.24% | 68.7% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Opko Health, Inc. | NA | NA | -2.87 | -0.37 | -0.13 | -0.05 | NA | 1.8 |
Idexx Laboratories, Inc. | 49.03 | 49.03 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.89 | 32.89 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.35 | 37.35 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 45.86 | 45.86 | 3.13 | 7.63 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.05 | 32.05 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Opko Health, Inc. | Buy | $857.3M | -50.41% | NA | -21.87% |
Idexx Laboratories, Inc. | Buy | $41.1B | 110.45% | 49.03 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 76.14% | 32.89 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $220.4B | 109.26% | 37.35 | 13.99% |
Danaher Corp. | Buy | $185.5B | 87.73% | 45.86 | 18.55% |
Iqvia Holdings Inc. | Buy | $42.6B | 68.7% | 32.05 | 9.06% |
Vanguard Group Inc
BlackRock Inc
Geode Capital Management, LLC
State Street Corporation
D. E. Shaw & Co LP
Goldman Sachs Group Inc
Opko Health, Inc.’s price-to-earnings ratio stands at None
Read Moreopko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Organization | Opko Health, Inc. |
Employees | 3930 |
CEO | Dr. Phillip Frost Ph.D. |
Industry | Health Technology |